CMV

FLORENCE | ITALY

FROM PREGNANCY TO INFANCY: LET’S FACE IT

cmvcongress.eu

21-22 FEBRUARY

2019

2

CONGRESS PRESIDENTS:

Yves Ville, FranceEfraim Bilavsky, Israel

FACULTY:

Jacob Amir, IsraelDaniel Blázquez-Gamero, SpainLinda de Vries, the Netherlands

Elisa Fabbri, ItalyIna Foulon, Belgium

Chrissie Jones, United KingdomAsma Khalil, United KingdomDavid Kimberlin, United States

Tiziana Lazzarotto, ItalyMarianne Leruez-Ville, France

Daniele Lilleri, ItalyShlomo Lipitz, IsraelAlbert Park, USA

Olivier Picone, FranceMark Schleiss, USA

Giuliana Simonazzi, ItalyNatasha Teissier, France

Ann Vossen, the Netherlands

3

FIRST DAYTHURSDAY 21 FEBRUARY 2019

09.00 - 09.10 WELCOME FROM CONGRESS PRESIDENTS

09.10 - 10.00 DEBATE Moderators: Shlomo Lipitz, Israel; Giuliana Simonazzi, Italy

Prenatal screening YES/NO Yves Ville/Asma Khalil

10.00 - 11.30 PREVENTION AND TREATMENT OF PRIMARY INFECTION DURING PREGNANCY Moderators: Tiziana Lazzarotto, Italy; Yves Ville, France

10.00 - 10.20 Attitude/educational and hygienic measures Olivier Picone, France

10.20 - 10.40 Antiviral treatment Marianne Leruez-Ville, France

10.40 - 11.00 Passive and active vaccinations during pregnancy Daniele Lilleri, Italy

11.00 - 11.10 Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects Rituparna Das, United States

11.10 - 11.20 Development of a digital antenatal educational intervention to reduce the risk of acquisition of CMV in pregnancy: working in partnership with pregnant women and families affected by CMV Chrissie Jones, United Kingdom

11.20 - 11.30 Panel Discussion

4

11.30 - 12.00 COFFEE BREAK

12.00 - 13.30 TREATMENT OF CHILDREN WITH CCMV Moderators: Jacob Amir, Israel; Daniel Blázquez-Gamero, Spain

12.00 - 12.20 Deciding to treat symptomatic congenital CMV: extent of involvement and use of biomarkers David Kimberlin, United States

12.20 - 12.40 Who is afraid of prolonged Valganciclovir treatment? Ann Vossen, The Netherlands

12.40 - 13.00 Treatment of Congenital CMV Infection: new populations, new regimens, and new drugs? David Kimberlin, United States

13.00 - 13.10 Targeting peptidyl arginine deiminase type 2 (PAD2) is a promising therapeutic option against congenital HCMV infections Marco De Andrea, Italy

13.10 - 13.20 Baseline Brain Magnetic Resonance Imaging (MRI) for Children with Congenital Cytomegalovirus (cCMV) - a retrospective analysis Hermione Lyall, United Kingdom

13.20 - 13.30 Panel Discussion

13.30 - 14.30 LUNCH BREAK

14.30 - 15.45 DIAGNOSIS OF FETAL DISEASE DURING PREGNANCY Moderators: Mark Schleiss, United States; Daniele Lilleri, Italy

14.30 - 14.55 How to diagnose a primary infection Tiziana Lazzarotto, Italy

14.55 - 15.15 How to diagnose a non primary infection Marianne Leruez-Ville, France

5

15.15 - 15.40 The value of ultrasound screening for CMV infection Giuliana Simonazzi, Italy

15.40 - 15.50 Role of ultrasound examination in predicting newborn sequelae in pregnancies complicated by Cytomegalovirus infection: a single center co-hort Agnese Comelli, Italy

15.50 - 16.00 CMV-DNA evaluation in maternal urine and plasma: the role on the vertical transmission Giuseppina Esposito, Italy

16.00 - 16.15 Panel Discussion

16.15 - 16.45 COFFEE BREAK

16.45 - 17.30 DEBATE ON PRO VS CONS ON NON-PRIMARY INFECTION DIAGNOSIS IN PREGNANCY Moderator: Chrissie Jones, United Kingdom Speakers: Marianne Leruez-Ville, France and Tiziana Lazzarotto, Italy

6

09.00 - 10.45 HEARING LOSS AND VESTIBULAR DISORDERS IN CCMV Moderators: Albert Park, United States; Efraim Bilavsky, Israel

09.00 - 09.25 Hearing rehabilitation in children with cCMV (including unilateral hearing loss) Ina Foulon, Belgium

09.25 - 09.50 Treatment of isolated hearing loss Chrissie Jones, United Kingdom

09.50 - 10.15 Vestibular disorders in children with congenital Cytomegalovirus Infection Natacha Teissier, France

10.15 - 10.25 Vestibular function in children with congenital cytomegalovirus infection: results of 2.5 years of follow-up Cleo Dhondt, Belgium

10.25 - 10.45 Panel Discussion

10.45 - 11.20 COFFEE BREAK

11.20 - 12.00 ACCEPTED ORAL LECTURES Moderators: Linda De Vries, The Netherlands; Ina Foulon, Belgium

11.20 - 11.30 Evaluation of a new molecular assay for newborn cytomegalovirus testing using oral dried swab samples Angela Chiereghin, Italy

11.30 - 11.40 Monitoring CMV infection in pregnancy in the province of Trento 2007-2016 Silvano Piffer, Italy

SECOND DAYFRIDAY 22 FEBRUARY 2019

7

11.40 - 11.50 Targeted neonatal screening for congenital CMV - a single center experience Joseph Pardo, Israel

11.50 - 12.00 Neonatal neuroimaging in symptomatic congenital CMV (cCMV) and its orrelation with outcome: emphasis on white matter disease Ana Alarcon, Spain

12.00 - 13.30 PROGNOSTIC EVALUATION OF FETAL INFECTION Moderators: Shlomo Lipitz, Israel; Daniele Lilleri, Italy

12.00 - 12.20 The right combination of ultrasound and MRI Yves Ville, France

12.20 - 12.40 Fetal blood prognostic factors Elisa Fabbri, Italy

12.40 - 13.00 The impact of cCMV on the brain of preterm infants Linda de vries, The Netherlands

13.00 - 13.10 Fetal neuroimaging as a prognostic tool for congenital CMV infection Jacob Amir, Israel

13.10 – 13.20 The role of MRI in fetal CMV infection Shlomo Lipitz, Israel

13.20 – 13.30 Panel Discussion

13.30 - 14.30 LUNCH BREAK

14.30 - 16.00 ACCEPTED ORAL LECTURES Moderators: David Kimberlin, United Sates; Ann Vossen, the Nether-lands

14.30 - 14.40 Congenital cytomegalovirus-associated hearing loss: can brain imaging predict hearing outcome? Ingeborg Dhooge, Belgium

8

14.40 - 14.50 Performance and outcome of a multi-hospital programmatic congenital cytomegalovirus (cCMV) universal newborn screening program John DeVincenzo, United States

14.50 - 15.00 Prevalence and clinical manifestations of congenital cytomegalovirus infection in a screening program in Madrid (PICCSA Study) Daniel Blázquez-Gamero, Spain

15.00 - 15.10 Another Look at Dried Blood Spot (DBS) PCR for Diagnosis of Congenital CMV (cCMV) Infection: Results from a Minnesota Universal Newborn Screening Study Mark Schleiss, United States

15.10 - 15.20 Universal congenital CMV infection (cCMV) screening: a three-years single center experience Simona Fiorentini, Italy

15.20 - 15.30 Treatment of children born with congenital cytomegalovirus infection beyond the neonatal period Lev Dorfman, Israel

15.30 - 15.40 Prospective multi-center comparison of urine culture with PCR from DBS using two different extraction and PCR methods in neonates Elizaveta Padalko, Belgium

15.40 - 15.50 Yield of urine for CMV screening test for asymptomatic micro-cephalic infants Haroon Usman, Ireland

9

15.50 - 16.40 DEBATE Moderators: David Kimberlin, United Sates; Ann Vossen, the Netherlands

Is it the time for universal screening for cCMV? YES Efraim Bilavky, Israel NO Ann Vossen, the Netherlands

16.40 CLOSING REMARKS Yves Ville, Efraim Bilavsky

10

POSTER LIST

PLEASE DISPLAY YOUR POSTER IN THE POSTER AREA ACCORDING TO YOUR NUMBER LISTED BELOW

1 SEVERE CONGENITAL CYTOMEGALOVIRUS INFECTION FOLLOWING EARLY RECURRENT INFECTION DURING PREGNANCY B. Resch; M. Grillitsch; M. Häusler; C. Koidl; E. Karpf; B. Urlesberger

2 SEVERE FORM OF THE HYDROTHORAX ASSOCIATED WITH RIGHT DIVIDED ATRIUM AND CYTOMEGALOVIRUS INFECTION - PRENATAL DIAGNOSIS AND OUTCOMES R.Bejiqi; R. Retkoceri; A. Maloku; N. Zeka; A. Vuçiterna; A. Mustafa; A. Gerguri; H. Bejiqi 2; R. Bejiqi

3 DESIGN OF AN ENLITE(TM) PCR ASSAY FOR THE DETECTION OF CONGENITAL CYTOMEGALOVIRUS I. Alm-Ndiaye; O. Leppänen; M. Mäkinen; M. Lehmusvaara; A. Ylikoski

4 SECONDARY HEMOPHAGOCYTIC SYNDROME TRIGGERED BY CONGENITAL CYTOMEGALOVIRUS INFECTION E.N. Balashova

5 VESTIBULAR FUNCTION AND MOTOR PERFORMANCE IN INFANTS WITH CONGENITAL CYTOMEGALOVIRUS INFECTION: A PRELIMINARY STUDY L. Maes; A. De Kegel; H. Van Waelvelde; E. De Leenheer; H. Van Hoecke; J. Goderis; I. Dhooge

6 PREVENTING CMV INFECTION THROUGH INFORMATION, EDUCATION AND COLLABORATION G. Johnson

7 PULMONARY HYPERTENSION AS A RARE COMPLICATION OF CONGENITAL CYTOMEGALOVIRUS L. Alkoby-Meshulam; J. Amir; D. Lubin; G. Kalinger; G. Gutsman; S. Zangen; E. Bilavsky

11

8 DOES T-CELL MEDIATED IMMUNE RESPONSE TO CYTOMEGALOVIRUS INFECTION PLAY A ROLE IN PREVENTING INTRAUTERINE TRANSMISSION? M. Soriano-Ramos; S. Domínguez-Rodríguez; D. Navarro; E. Albert; M. De La Calle; M. Cabanes; F. Baquero-Artigao; P. Rodríguez Molino; A. García Burguillo; A. Goncé; D. García; E. Gómez; I. Cuadrado; M. C. Viñuela Benéitez; M. Muñ

9 FETAL LIVER VOLUME ASSESSMENT USING MAGNETIC RESONANCE IMAGING IN FETUSES WITH CMV INFECTION A. Hawkins-Villarreal; A. Moreno-Espinosa; N. Hahner; E. Eixarch; A. Nadal; A. Goncé

10 EVIDENCE OF RESISTANCE IN NEONATAL LONG-TERM VALGANCICLOVIR THERAPY F. Garofoli; M. Angelini; C. Achille; M. Zavattoni; L. Bollani; G. Lombardi

11 CMV INFECTION REACTIVATION IN A TWIN PREGNANCY P. Prats; S. Coll; A. Ponce; C. Fortuny; B. Serra

12 SUCCESSFUL TREATMENT OF INTRAUTERINE CYTOMEGALOVIRUS INFECTION OF THE FETUS AND NEWBORN A. Mikhailov ; A. Romanovsky; T. Kashtanova; I. Kyanksep; N. Rogozina; A.Grineva; I. Bazarov

13 DETECTION AND QUANTIFICATION OF CMV IN AMNIOTIC FLUID, URINE AND SALIVA SWAB A. Derome; P. Marechal; C. Kappler; F. Gelas

14 LONG-TERM HEARING AND NEURODEVELOPMENTAL OUTCOMES AMONG CHILDREN WITH SYMPTOMATIC CONGENITAL CMV DISEASE WITH AND WITHOUT GANCICLOVIR THERAPY T.M. Lanzieri; A.C. Caviness; J. Leung; W. Chung; J.L. Baumgardner; R.G. Voigt; P. Blum; S.R. Bialek; G. Demmler-Harrison

15 WHAT DOES THE HALO SIGN MEAN IN FETAL CMV INFECTION? EVALUATION OF SONOGRAPHIC AND HISTOLOGICAL FINDINGS IN 13 CASES A. Goncé; A. Hawkins-Villarreal; E. Eixarch; A. Nadal; S. Planas; F. Figueras 16 FLUCTUATION IN VIRAL LOAD AFTER TREATMENT FOR CONGENITAL CYTOMEGALOVIRUS: A CASE REPORT A. Afjeh; P.Alizadeh

12

17 CONGENITAL CYTOMEGALOVIRUS INFECTION - DIFFERENT MANIFESTATION AND CONSEQUENCES IN TWO CASES S. Prgomet; T. Bošnjak; I. Antončič Furlan 3; G. Tešovič 18 MATERNAL FETAL INFECTIONS AND LONG TERM NEURODEVELOPMENTAL OUTCOMES IN CHILDREN INFECTED AND UNINFECTED AT BIRTH C. Auriti; S. Bucci; M.P. Ronchetti; A. Santisi; F. Piersigilli; S. Lozzi; I. Bersani; F. Campi; S. Gentile; A. Dotta

19 A NEW MRI SEVERITY SCORE TO PREDICT LONG-TERM ADVERSE NEUROLOGIC OUTCOMES IN CHILDREN WITH CONGENITAL CYTOMEGALOVIRUS INFECTION G. Lucignani; M.C. Rossi Espagne; A. Napolitano; L. Figà Talamanca; F.I.Calò Carducci; C.Auriti; D.Longo

20 SYMPTOMATIC CONGENITAL CYTOMEGALOVIRUS INFECTION IN NEWBORNS: BIRTH PREVALENCE AND RISK FACTORS A. Vaniarkina; A. Petrova; L. Rychkova

21 CONGENITAL CYTOMEGALOVIRUS INFECTION IN HIV-EXPOSED UNINFECTED NEWBORNS A. Petrova ; A.Vaniarkina

22 NEUROCOGNITIVE OUTCOME IN SYMPTOMATIC AND ASYMPTOMATIC NEWBORNS WITH CONGENITAL CMV TREATED WITH VALGANCICLOVIR A. Turriziani Colonna; D. Pata; V. Faccia; E. Masiello; G. Salerno; D. Buonsenso; P. Valentini

23 THE IMPORTANCE OF THE POORER-HEARING EAR IN CMV AND ISOLATED HEARING LOSS A. Park; V. Torrecillas; C. Allen; T. Greene; G. Demmler-Harrison

24 CMV CONGENITAL INFECTION: RETROSPECTIVE ANALYSIS OF MATERNAL SEROLOGIES DURING PREGNANCY C. Perillaud Dubois; E. Letamendia; E. Bouthry ; M.F. Lepetitcorps ; A. Benachi ; C. Vauloup Fellous

25 CONGENITAL CYTOMEGALOVIRUS INFECTION WITH MINOR LESIONS AT FETAL MRI: A 12 YEARS EXPERIENCE TO IMPROVE COUNSELLING SKILLS C. Doneda; B. Scelsam; P. Introvini; M. Zavattoni; S. Orcesi; G. Lombardi; L. Pugni; M. Fumagalli; M. Rustico; E. Fabbri; V. Tien Tu; G. Izzo; M. Genovese; C. Parazzini; B. Tassis; A. Ronchi; C. Pietrasanta; F. Triulzi

13

26 CMV INFECTION: RELATIVES BETWEEN MOTHER’S AMNION FLUID AND THEIR CHILDREN’S UMBILICAL BLOOD C. Perillaud Dubois; E. Letamendia; E. Bouthry; M.F. Lepetitcorps; A. Benachi; C. Vauloup Fellous 27 FETAL CMV INFECTION, DILEMMA FOR DIAGNOSIS AND PROGNOSIS N. Vedmedovska; A. Miskova; A. Krumiča; S. Dzelzite; L. Smane

28 PROSPECTIVE STUDY ON SENSORINEURAL HEARING LOSS (SNHL) IN A COHORT OF INFANTS WITH CONGENITAL CYTOMEGALOVIRUS (cCMV) INFECTION C. Marsico; M. G. Capretti; C. S. Nigro; L. Gabrielli; C. Brandolini; A. Benatti; G. Faldella; T. Lazzarotto

29 SEVERE CONGENITAL CYTOMEGALOVIRUS INFECTION J. Figueirinha; C. Ferreira; D. Bordalo; S. Rolim; M. Figueiredo; A. Pereira; S. Tomé

30 SECOND TRIMESTER SONOGRAPHIC SIGNS OF FETAL CMV LESIONS WITHOUT MATERNAL CONFIRMATION OF CMV INFECTION F. Monacci; F. Strigini; M. Pistello; R. Canapicchi; V. Nardini; T. Simoncini

31 THE NATURAL HISTORY OF HEARING DISORDERS IN ASYMPTOMATIC CONGENITAL CYTOMEGALOVIRUS INFECTION S. Salomè; A. Giannattasio; R. Malesci; E. Marciano; P. Dolce; G. Portella; P. Di Costanzo; E. Capone; C. Coppola; L. Capasso; F. Raimondi

32 CONGENITAL CYTOMEGALOVIRUS INFECTION AWARENESS AMONG PRENATAL HEALTH CARE PROVIDERS FOR WOMEN GIVING BIRTH AT A TERTIARY REFERRAL HOSPITAL IN BARCELONA (SPAIN) M. Valdés-Bango 1; K. Castillo; A. Hawkins ; L. Guirado ; E. Scazzocchio; F. Figueras; A. Goncé

33 CMV INFECTION IN PEDIATRIC RESIDENTS: EPIDEMIOLOGY AND AWARENESS P. Rodríguez Molino; T. del Rosal; C. Calvo; M. Muñoz San José; D. Blázquez Gamero; Maria José Mellado; M. de la Calle; M. Cabanes Borrallo; F. Baquero-Artigao

34 INVESTIGATION OF CYTOMEGALOVIRUS-SPECIFIC IGM: COMPARISON BETWEEN THREE COMMERCIAL KITS AND IMMUNOBLOTTING T. Lazzarotto; A. Chiereghin; G.Turello; E.C. Borgatti; G. Piccirilli; I. Cataneo; L. Gabrielli; G. Simonazzi

14

35 HIGH CMV REPLICATION IN THE FOETAL HIPPOCAMPUS G. Piccirilli; L. Gabrielli; A. Chiereghin; M.P. Bonasoni; G. Turello; E. C. Borgatti; G. Simonazzi; N. Salfi; C. Ceccarelli; D. Santini; T. Lazzarotto

36 CONGENITAL CMV AFTER SECONDARY MATERNAL INFECTION. PRENATAL POSTNATAL CORRELATION CASE REPORT A.M. Martinez Sapiña; J. Pascual Mancho; V. Paris Boj; R. M. Fernandez Esgueva; Pinillos Pison; P. Abenia; P. Seral; M.C.Tajada Duaso

37 PRENATAL ULTRASOUND FEATURES IN CONGENITAL CYTOMEGALOVIRUS M. Lanna; E. Fabbri; A Quarenghi; S. Faiola; A Garofalo; C. Doneda; I. Cetin; M.A. Rustico

38 TREATMENT OF PRETERM INFANTS WITH CONGENITAL CMV INFECTION F. Lorenzoni; M. Del Pistoia; S. D’Elios; M. Ferrara; M. Ciantelli; P. Ghirri

39 DOES VALGANCICLOVIR TREATMENT IMPROVE WHITE MATTER ABNORMALITIES IN CONGENITAL CYTOMEGALOVIRUS INFECTION? G. Forner; F. De Osti; E. Trincia; M. Bendini; I. Inches; E. Vian; N. Mainin

40 FETAL TREATMENT OF CMV INFECTION WITH VALACICLOVIR – A SINGLE CENTER EXPERIENCE – LISBON 2004-2018 M. Martins; A. Cohen

41 ROLE OF GLYCOPROTEIN (G)O AND GH GENOTYPES IN CONGENITAL CMV INFECTION: SEARCHING FOR VIRAL PROGNOSTIC MARKERS I. Taravillo; N. Moral; C. Pascual; A. Pérez-Rivilla; M.D. Folgueira

42 COUNSELING AND PRENATAL DIAGNOSIS OF CYTOMEGALOVIRUS: 20 YEARS’ EXPERIENCE OF AN ITALIAN REGIONAL REFERENCE CENTRE G. Esposito; A. Giudicepietro; S. Tagliaferri; L. L. Mazzarelli; L. Sarno; A. Sirico; F.Quaglia; G. Saccone; T. Guerritore; M. Di Cresce; F. Zullo; P. Martinelli; G.M. Maruotti

43 AMNIOCENTESIS FOR PRENATAL DIAGNOSIS OF CYTOMEGALOVIRUS INFECTION: WHAT COUNSELING AFTER A NEGATIVE PCR OF CMV-DNA? G. Esposito; S. Salomè; A. Giudicepietro; S. Tagliaferri; L. L. Mazzarelli; L. Sarno; A. Sirico; P. Di Costanzo; C. Coppola; G. Saccone; F. Zullo; P. Martinelli; F. Raimondi; G. M. Maruotti

15

44 DIAGNOSIS OF FETAL CMV INFECTION DURING PREGNANCY M. Fernández-Esgueva; J. Pascual-Mancho; R. Pinillos-Pison; P. Abenia-Uson; M. L. Roc-Alfaro; A. Martinez-Sapiña

45 CMV INFECTION RATE DURING PREGNANCY IN GREECE: ONE YEAR STUDY D. Bountouvas; D. Lampropoulou; E. Alchazidou; G. Petrakos

46 CYTOMEGALOVIRUS IN PREGNANCY: AN OBSERVATIONAL STUDY TO ASSESS OBSTETRIC PROVIDER KNOWLEDGE ABOUT PREVENTIVE PRACTICES AND DIAGNOSIS C. Boccherini; V. D’Ambrosio; F. Vena; S. Corno; C. Pajno; P. Ciolli; F. Rech; R. Brunelli; D. Di Mascio; P. Benedetti Panici; A. Giancotti

47 KNOWLEDGE OF CONGENITAL CYTOMEGALOVIRUS (CCMV) AMONG PREGNANT WOMEN ATTENDING ANTENATAL CARE UNIT IN A TERTIARY PERINATAL CENTER F. Vena; V. D’Ambrosio; C. Boccherini; C. Pajno; S. Corno; P. Ciolli; F. Rech; D. Di Mascio; R. Brunelli P. Benedetti Panici; A. Giancotti

48 SCREENING, DIAGNOSIS AND TREATMENT CCMV N. Vaynshteyn; E. Britanishskaya; J. Mitina; T. Matveeva; H. Sarkisyan; Z. Morozova

49 SEVERE CCMV INFECTION, CASE REPORT N. Vaynshteyn; E. Britanishskaya; J. Mitina; T. Matveeva; H. Sarkisyan; Z. Morozova

50 CMV ENTEROCOLITIS IN NEONATES, THREE CASE REPORTS N. Vaynshteyn; E. Britanishskaya; J. Mitina; T. Matveeva; A. Chubarova; N. Krivova

51 CONGENITAL CMV INFECTION – 8 YEAR EXPERIENCE OF A PORTUGUESE CENTER I. Ferreira; A. Amorim; E. Martins; M. Ferreira; R. Barroso

52 HYPERIMMUNOGLOBULIN THERAPY. PORTUGUESE PRENATAL DIAGNOSIS CENTER´S EXPERIENCE J. R. Silva; M.M Carrilho; F. Valente

53 THE EFFICACY OF ANTIVIRAL TREATMENT IN INFANTS WITH CONGENITAL CYTOMEGALOVIRUS INFECTION WITH OR WITHOUT HEARING LOSS D. Ari-Even Roth; M. Tepperberg-Oikawa; Y. Henkin; G. Barkai

16

WITH SPECIAL THANKS TO

17

COMPANY PROFILES

ROCHE

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

MERIDIAN BIOSCIENCE, INC.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.

18

ELITECH

ELITechGroup manufactures and distributes diagnostic products for clinical chemistry, microbiology, hematology and molecular biology though direct sales and a distribution network encompassing more than 100 countries.ELITechGroup is a leading PCR innovator with the revolutionary Minor Groove Binder technology and has become today a global solution provider for Molecular Diagnostics. Our culture of innovation, combined with the highest manufacturing quality standard and long-lasting collaborations with customers and international working groups enables us to design and manufacture superior sensitivity and specificity real-time PCR assays for infectious disease testing, immunocompromised patient monitoring, antibiotic resistance control, oncohematology, and genetic testing.

MSD

MSD Italia is the Italian affiliate of Merck & Co., Inc., NJ, USA, which is in over 140 countries with 70,000 employees, providing innovative healthcare solutions and increasing access to therapies through targeted policies, programs and partnerships. In Italy the Company operates since 1956 with productive, commercial and research activities providing medicines, vaccines, biological therapies and animal health products

BIOMÉRIEUX

BioMérieux is a world leader in the field of in vitro diagnostics and has a longstanding commitment to the fight against infectious diseases. We provide diagnostic solutions that include bacteriology & virology reagents, instruments, IT solutions and services along with the leading BioFire Syndromic testing products. Each of our products is designed to allow clinicians to take more rapid and informed clinical decisions with actionable results to fight antimicrobial resistance and reduce inappropriate antibiotic use for better patient care.bioMérieux is present worldwide in more than 150 countries through 43 subsidiaries and distributors.

19

GENERAL INFORMATION

CONGRESS VENUE

Istituto degli Innocenti Piazza della Santissima Annunziata, 12, 50122 Firenze FI

CONGRESS MATERIAL

Participants can collect badge and congress material at the Registration desk located at the Salone delle Compagnie.Please note that admission to Scientific Session and exhibition area is restricted to participants wearing their badge

ORGANIZING SECETARIAT

MCA Events Srl Via Ambrogio Binda, 34 20143 Milano - Italy Ph. +39 02 34934404 | Fax +39 02 34934397 info@mcascientificevents.eu www.mcascientificevents.eu

OPENING HOURS

Thursday, February 21st From 08.00 am to 5.30 pm Friday, February 22nd From 08.30 am to 4.40 pm

OFFICIAL LANGUAGE

English is the official language of the Congress.

20

CERTIFICATE OF ATTENDANCE

The Certificate of Attendance will be available to download on www.cmvcongress.eu at the end of the Congress.

INTERNATIONAL ACCREDITATION (UEMS)

UEMS – European Union of Medical Specialists: 10 credits recognized. The “CONGENITAL CMV – FROM PREGNANCY TO INFANCY: LET’S FACE IT” has been accredited by the European Accreditation Council for Continuing Medical Educational (EACCME) for the entire congress. EACCME credits are recognized Europe-wide and in North America they can be exchanged for their national equivalent by contacting your national CME authority.

ITALIAN ACCREDITATION (ECM – EDUCAZIONE CONTINUA IN MEDICINA)

N. EVENTO: 246907CREDITI ASSEGNATI: 7 CREDITI

Il Congresso è stato accreditato per le seguenti categorie:

· MEDICO CHIRURGO Discipline: Neonatologia, Pediatria, Pediatria (Pediatri di libera scelta), Ginecologia e Ostetricia

· INFERMIERE · INFERMIERE PEDIATRICO· OSTETRICA/O

L’erogazione dei crediti ECM da parte del provider è subordinata a:

1. alla partecipazione effettiva del 90% rispetto alla durata complessiva dell’evento formativo 2. alla compilazione del questionario di gradimento online3. alla corrispondenza tra la professione svolta e le discipline dichiarate, dal provider, al momento della richiesta di accreditamento 4. alla correttezza e completezza dei dati forniti su richiesta nella scheda anagrafica compilata.

21

NOTE

22

NOTE

23

NOTE

mcascientificevents.eu

cmvcongress.eu